Teva Reintroduces Depo-Provera Generic in the U.S.

Sep 26, 2017

Teva is relaunching its generic contraceptive injection drug Depo-Provera, which is indicated to prevent pregnancy, in the United States.

According to Teva, it is reintroducing the product because it feels the drug brings something to a market lacking options. Teva EVP and president of global generics research and development Dr. Hafrun Fridriksdottir said that this move also "holds significant importance to Teva and our generics R&D priorities.”

Depo-Provera had US sales of about $211 million, according to IMS data as of July 2017.

Read the press release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments